Medicare Will Pay Less for Ozempic and Wegovy in 2027. The Price-Negotiation List Is Out.
Medicare will soon start paying lower prices for Novo Nordisk’s weight- loss drug Wegovy and its Type 2 diabetes treatment ...
STAT3d
A biotech legend, pharma CEO, and two Trump admin vets walk into JPM Day 2
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Insider Monkey3d
Jim Cramer on Pfizer Inc. (PFE) CEO Albert Bourla: ‘President-elect Trump Felt That Bourla Was A Hero During COVID’
Its high debt load remained a cause of investor concern for the entire year, and as a result, CEO Albert Bourla’s turnaround strategy is now a key part of Pfizer Inc. (NYSE:PFE)’s hypothesis.
Pfizer Eyes $20 Billion Revenue From Acquisitions Amid Patent Cliff Challenges
While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I ...
BioSpace3d
Pfizer Cautiously Optimistic on Obesity Pill as Kailera Challenges Lilly’s Zepbound With Strong Phase II Data
Obesity continues to grab attention at the J.P. Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera ...
GlobalData on MSN4d
Pfizer pitches pipeline priorities in oncology and obesity at JP Morgan 2025
CEO Albert Bourla expressed modest optimism for Pfizer’s 2025 revenues at JPM 2025, supported by plans to prioritize R&D in ...
FiercePharma3d
JPM25: BMS, Pfizer and Merck CEOs address key patent cliffs and plans to replace sales
Monday, three Big Pharma leaders took center stage and addressed concerns about future patent expirations head-on.
Pfizer CEO Is Optimistic Ahead of the Trump Administration. ‘The Opportunities Outweigh the Risks.’
Pfizer CEO Albert Bourla said he had spoken to Robert F. Kennedy Jr. in an effort to “find opportunities on things we can ...